Hormonal
Higher doses (10-15 mg) of the dual GIP/GLP-1 receptor agonist tirzepatide significantly improve specific nonalcoholic steatohepatitis (NASH) biomarkers, including reducing hepatocyte apoptosis (K-18) and fibrosis (Pro-C3), and increasing anti-fibrogenic adiponectin, in patients with type 2 diabetes.
If you have Type 2 Diabetes, higher doses of tirzepatide (10-15 mg weekly) have been shown to improve blood markers associated with liver inflammation and scarring (NASH) compared to placebo. However, this is based on blood tests, not liver biopsies, so it indicates reduced liver stress rather than a confirmed cure for liver disease. Consult your doctor to see if this medication is appropriate for your metabolic health.
In post hoc analyses, higher tirzepatide doses significantly decreased NASH-related biomarkers and increased adiponectin in patients with T2DM.
Why this rating
The study is a post hoc analysis of a phase 2 trial with a relatively small sample size (N=316) and no liver biopsy confirmation of NASH in all patients, limiting the strength of the conclusion.
Source
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman et al. · Diabetes Care · 2020
DOI 10.2337/dc19-1892
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →